Rapamycin Treatment Improves Neuron Viability in an in Vitro Model of Stroke

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Jul 18

PMID 23861877

Citations 26

Authors

Lauren Fletcher

Teresa M Evans

Lora Talley Watts

David F Jimenez

Murat Digicaylioglu

Affiliations

Soon will be listed here.

Abstract

Ischemic stroke is the leading cause of serious, long-term adult disability and is associated with sensorimotor and cognitive impairments due to neuronal degeneration. Currently, recombinant tissue plasminogen activator (rTPA) is the only FDA-approved medical therapy for treatment of patients with acute ischemic stroke. However, rTPA can only be given within 3 hours of symptom onset, and only 2% of patients are eligible. Therefore, there is an urgent need for novel neuroprotective treatment options for ischemic stroke. An emerging treatment for a diverse range of neurological disorders associated with neurodegeneration is rapamycin, a key modulator of the mammalian target of rapamycin (mTOR) pathway. The mTOR pathway is the primary regulator of the cellular response to nutrient availability, changes in energy status and stress as seen following ischemia and reperfusion. However, rapamycin's effects on mTORC1 and mTORC2 are poorly understood in neurons. In the current study we show that rapamycin can prevent the activation of both mTORC1 and mTORC2 in cortical neurons and improve cell survival following oxygen glucose deprivation (OGD), an in vitro model of ischemic stroke. This work further supports the investigation of rapamycin as a novel neuroprotectant for ischemic stroke.

Citing Articles

Rapamycin Treatment Reduces Brain Pericyte Constriction in Ischemic Stroke.

Beard D, Brown L, Morris G, Couch Y, Adriaanse B, Karali C Transl Stroke Res. 2024; .

PMID: 39331260 DOI: 10.1007/s12975-024-01298-x.

The involvement of Akt, mTOR, and S6K in the in vivo effect of IGF-1 on the regulation of rat cardiac Na/K-ATPase.

Banjac K, Obradovic M, Zafirovic S, Essack M, Gluvic Z, Sunderic M Mol Biol Rep. 2024; 51(1):517.

PMID: 38622478 DOI: 10.1007/s11033-024-09451-3.

Pharmacological inhibition of mTORC1 reduces neural death and damage volume after MCAO by modulating microglial reactivity.

Villa-Gonzalez M, Rubio M, Martin-Lopez G, Mallavibarrena P, Valles-Saiz L, Vivien D Biol Direct. 2024; 19(1):26.

PMID: 38582839 PMC: 10999095. DOI: 10.1186/s13062-024-00470-5.

Metabolic transitions regulate global protein fatty acylation.

Talwadekar M, Khatri S, Balaji C, Chakraborty A, Basak N, Kamat S J Biol Chem. 2023; 300(1):105563.

PMID: 38101568 PMC: 10808961. DOI: 10.1016/j.jbc.2023.105563.

A Novel Bioactive Peptide, T14, Selectively Activates mTORC1 Signalling: Therapeutic Implications for Neurodegeneration and Other Rapamycin-Sensitive Applications.

Ranglani S, Ashton A, Mahfooz K, Komorowska J, Graur A, Kabbani N Int J Mol Sci. 2023; 24(12).

PMID: 37373106 PMC: 10298579. DOI: 10.3390/ijms24129961.

References

Spilman P, Podlutskaya N, Hart M, Debnath J, Gorostiza O, Bredesen D . Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One. 2010; 5(4):e9979. PMC: 2848616. DOI: 10.1371/journal.pone.0009979. View

Sengupta S, Peterson T, Sabatini D . Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010; 40(2):310-22. PMC: 2993060. DOI: 10.1016/j.molcel.2010.09.026. View

Caccamo A, Majumder S, Richardson A, Strong R, Oddo S . Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem. 2010; 285(17):13107-20. PMC: 2857107. DOI: 10.1074/jbc.M110.100420. View

Broughton B, Reutens D, Sobey C . Apoptotic mechanisms after cerebral ischemia. Stroke. 2009; 40(5):e331-9. DOI: 10.1161/STROKEAHA.108.531632. View

Cimarosti H, Henley J . Investigating the mechanisms underlying neuronal death in ischemia using in vitro oxygen-glucose deprivation: potential involvement of protein SUMOylation. Neuroscientist. 2008; 14(6):626-36. PMC: 3310903. DOI: 10.1177/1073858408322677. View

Read D, Gorman A . Involvement of Akt in neurite outgrowth. Cell Mol Life Sci. 2009; 66(18):2975-84. PMC: 11115732. DOI: 10.1007/s00018-009-0057-8. View

Chen J, Zheng X, Brown E, Schreiber S . Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A. 1995; 92(11):4947-51. PMC: 41824. DOI: 10.1073/pnas.92.11.4947. View

Adams H, Adams R, Del Zoppo G, Goldstein L . Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke. 2005; 36(4):916-23. DOI: 10.1161/01.STR.0000163257.66207.2d. View

Liebeskind D . Reperfusion for acute ischemic stroke: arterial revascularization and collateral therapeutics. Curr Opin Neurol. 2009; 23(1):36-45. DOI: 10.1097/WCO.0b013e328334da32. View

10.

Copp J, Manning G, Hunter T . TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 2009; 69(5):1821-7. PMC: 2652681. DOI: 10.1158/0008-5472.CAN-08-3014. View

11.

Xu Y, Zhang Q, Yu S, Yang Y, Ding F . The protective effects of chitooligosaccharides against glucose deprivation-induced cell apoptosis in cultured cortical neurons through activation of PI3K/Akt and MEK/ERK1/2 pathways. Brain Res. 2010; 1375:49-58. DOI: 10.1016/j.brainres.2010.12.029. View

12.

Li W, Petrimpol M, Molle K, Hall M, Battegay E, Humar R . Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res. 2006; 100(1):79-87. DOI: 10.1161/01.RES.0000253094.03023.3f. View

13.

Dowling R, Topisirovic I, Fonseca B, Sonenberg N . Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2009; 1804(3):433-9. DOI: 10.1016/j.bbapap.2009.12.001. View

14.

Fahling M . Cellular oxygen sensing, signalling and how to survive translational arrest in hypoxia. Acta Physiol (Oxf). 2008; 195(2):205-30. DOI: 10.1111/j.1748-1716.2008.01894.x. View

15.

Niizuma K, Endo H, Chan P . Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem. 2009; 109 Suppl 1:133-8. PMC: 2679225. DOI: 10.1111/j.1471-4159.2009.05897.x. View

16.

Lloyd-Jones D, Adams R, Brown T, Carnethon M, Dai S, de Simone G . Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010; 121(7):948-54. DOI: 10.1161/CIRCULATIONAHA.109.192666. View

17.

Foster K, Fingar D . Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem. 2010; 285(19):14071-7. PMC: 2863215. DOI: 10.1074/jbc.R109.094003. View

18.

Kroczynska B, Kaur S, Platanias L . Growth suppressive cytokines and the AKT/mTOR pathway. Cytokine. 2009; 48(1-2):138-43. DOI: 10.1016/j.cyto.2009.07.009. View

19.

Yuan Y, Guo Q, Ye Z, Pingping X, Wang N, Song Z . Ischemic postconditioning protects brain from ischemia/reperfusion injury by attenuating endoplasmic reticulum stress-induced apoptosis through PI3K-Akt pathway. Brain Res. 2010; 1367:85-93. DOI: 10.1016/j.brainres.2010.10.017. View

20.

Hara K, Yonezawa K, Weng Q, Kozlowski M, Belham C, Avruch J . Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem. 1998; 273(23):14484-94. DOI: 10.1074/jbc.273.23.14484. View